In the largest move since approving Tirzepatide for chronic weight management in November of 2023, the FDA has posted the approval of a single-dose vial presentation of Zepbound. With the complexity of manufacturing the current single-dose pens, single dose vial presentations could prove to be an answer to increasing manufacturing shortages of Tirzepatide for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The FDA approved the single-dose vials of Mounjaro in July of 2023, but Eli Lilly has elected to offer that presentation in x-US markets only.
top of page
bottom of page
コメント